These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6761857)

  • 21. Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study.
    Penne EL; Blankestijn PJ; Bots ML; van den Dorpel MA; Grooteman MP; Nubé MJ; ter Wee PM;
    Semin Dial; 2005; 18(1):47-51. PubMed ID: 15663765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Roles of organic anion transporters in the progression of chronic renal failure.
    Enomoto A; Niwa T
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S27-31. PubMed ID: 17976081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of body burden of uremic toxins.
    Ihle BU; Cox RW; Dunn SR; Simenhoff ML
    Clin Nephrol; 1984 Aug; 22(2):82-9. PubMed ID: 6383674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accumulation and excretion of middle molecules.
    Asaba H
    Clin Nephrol; 1983 Mar; 19(3):116-23. PubMed ID: 6839560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program].
    Mydlík M; Dzúrik R; Derzsiová K; Spustová V
    Cas Lek Cesk; 1983 Dec; 122(51):1573-6. PubMed ID: 6652672
    [No Abstract]   [Full Text] [Related]  

  • 26. An update on uremic toxins.
    Ringoir S
    Kidney Int Suppl; 1997 Nov; 62():S2-4. PubMed ID: 9350668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Middle molecules in patients with pre-dialysis chronic renal failure: a comparative clearance study.
    Schindhelm K; Lustenberger N; Nordmeyer C; Farrell P; Stolte H
    Clin Nephrol; 1982 Apr; 17(4):200-5. PubMed ID: 7075036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amino acid and protein metabolism in renal failure.
    Kopple JD; Jones M; Fukuda S; Swendseid ME
    Am J Clin Nutr; 1978 Sep; 31(9):1532-40. PubMed ID: 685869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Uremic toxins].
    Vanholder R
    Nephrologie; 2003; 24(7):373-6. PubMed ID: 14650749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of hemoperfusion as an adjunct to hemodialysis.
    Trafford A; Ireland R; Evans R
    Artif Organs; 1979 Aug; 3(3):249-52. PubMed ID: 533415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Separation, identification of uremic middle molecules, and preliminary study on their toxicity.
    Li G; Chu J; Liu X; Yuan Z
    Clin Chim Acta; 2004 Dec; 350(1-2):89-98. PubMed ID: 15530464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A potent inhibitor of cell proliferation in "middle molecules" isolated from the urine of uremic patients.
    Navarro J; Gerlier D; Touraine JL; Later R; Contreras P; Dore JF; Traeger J
    Biomedicine; 1979 Dec; 31(9-10):261-4. PubMed ID: 543928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Uremic toxins. Chromatographic profiles of substances of low and medium molecular weight].
    Nesse AB; Arrizurieta de Muchnik E
    Medicina (B Aires); 1984; 44(2):117-26. PubMed ID: 6537452
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 35. [Blood and urinary middle molecules in the diagnosis of inflammatory urological diseases and chronic kidney failure and the evaluation of plasmapheresis effectiveness].
    Kozlov VA; Chudnovskaia MV; Danilkov AP; Solov'ev NK
    Urol Nefrol (Mosk); 1987; (4):12-7. PubMed ID: 3660505
    [No Abstract]   [Full Text] [Related]  

  • 36. [Nature of the organic lesions in uremic poisoning].
    Beliakov NA; Levanovich VV; Solomennikov AV; Malakhova MIa; Pirgach NV
    Vestn Khir Im I I Grek; 1986 Oct; 137(10):122-7. PubMed ID: 3798647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Middle molecules evaluation in chronic renal failure during conservative treatment.
    Severini G; Carta S; Taccone-Gallucci M; Mazzarella V; Iacona A; Meloni C; Casciani CU
    Ann Ist Super Sanita; 1983; 19(2-3):417-9. PubMed ID: 6681233
    [No Abstract]   [Full Text] [Related]  

  • 38. Blood levels of middle molecules and their effects on motor nerve conduction velocity.
    Botella J; Gea T; Sanz-Guajardo D; Criado M; Torres MT; Guardiola J
    Artif Organs; 1981; 4 Suppl():151-5. PubMed ID: 7295082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The pathophysiology and pathobiochemistry of uremia].
    Hodler J; Hunkeler H
    Med Klin; 1976 Jan; 71(3):77-86. PubMed ID: 765707
    [No Abstract]   [Full Text] [Related]  

  • 40. Growth hormone treatment of short children with chronic renal failure before and after renal transplantation: rationale and recent results.
    Mehls O; Wühl E; Haffner D; Schaefer F; Tönshoff B
    Nephrol Dial Transplant; 1996 Sep; 11(9):1747-50. PubMed ID: 8918616
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.